Form 4: Cidara Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
Taylor Sandison, Chief Medical Officer of Cidara Therapeutics, acquired stock options on September 30, 2024, according to a Form 4 filing.
Summary
- Taylor Sandison, the Chief Medical Officer of Cidara Therapeutics, acquired 166,836 employee stock options on September 30, 2024.
- The exercise price of these options is $10.75.
- The options vest in 36 equal monthly installments starting from September 30, 2024, and expire on September 29, 2034.
- Following the transaction, Sandison directly owns 166,836 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports the acquisition of stock options by a company executive, which is a routine transaction.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with company performance.
Stakeholder Impact
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of earliest transaction and vesting commencement date. |
| 09/29/2034 | Expiration date of the stock options. |
| 10/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.